Accendra Health Flags 2026 Adjusted EBITDA Up to 30% Below Prior Outlook
Accendra Health said full-year 2026 net revenue is expected at the bottom end of its previous $2.45 billion–$2.55 billion outlook. The company also said adjusted EBITDA could be as much as 30% below the prior outlook’s $310 million midpoint, implying approximately $217 million at the low end; no precise revised EBITDA range was provided in the supplied material.
The supplied material directly reports that Accendra Health expects 2026 revenue at the low end of its previous range and that adjusted EBITDA could be as much as 30% below the prior $310 million midpoint. This is a new, forward-looking business-performance update with material implications for expected earnings and cash generation. The wording preserves the conditional nature of the EBITDA estimate, and the approximately $217 million figure is presented only as an implied downside case rather than revised company guidance. Importance is high because the potential EBITDA reduction is substantial, while surprise is below the maximum because market consensus and the precise revised outlook are not provided. The timestamp is estimated from the November 5 announcement and supplied publication timing. Only ACH is approved because the other companies listed have speculative sector read-throughs or no disclosed direct relationship to Accendra Health. The prior new-event classification is retained because no matching existing event was supplied.
Accendra Health expects 2026 net revenue at the bottom end of its prior $2.45B–$2.55B range and adjusted EBITDA could be up to 30% below the prior $310M midpoint.